Tesamorelin 5mg, Ipamorelin 5mg + MOTS-C 10mg Research Bundle
USA Made, ≥99% Purity Per Compound
4.9 177 verified reviews- Separate retail vials: Tesamorelin 5mg; Ipamorelin 5mg; MOTS-C 10mg
- USA manufactured in a Certified GMP California and Arizona laboratory.
- ≥99% purity target per compound with independent third-party HPLC, mass spectrometry, and batch-specific COAs
For research purposes only. Not intended for human consumption, medical use, diagnosis, treatment, or prevention of disease.
Per-compound specifications
3 vialsNothing in this bundle is co-formulated. Each vial keeps its own identity, purity target, and certificate, and is specified separately below.
- CAS
- 218949-48-5
- Molecular mass
- 5,136 g/mol
- Purity target
- ≥99%
- Form
- Lyophilized Powder
- CAS
- 170851-70-4
- Molecular mass
- 711.9 g/mol
- Purity target
- ≥99%
- Form
- Lyophilized Powder
- CAS
- 1627580-64-6
- Molecular mass
- 2,174.6 g/mol
- Purity target
- ≥99%
- Form
- Lyophilized Powder
- Form
- 3 Separate Lyophilized Powders
- Purity target
- ≥99% per compound (3rd-Party HPLC Tested)
- Origin
- All Included Products: Synthesized, Formulated & Packaged in CA/AZ, USA
- Storage
- Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light
What is the Tesamorelin 5mg, Ipamorelin 5mg + MOTS-C 10mg Research Bundle?
This three-vial research bundle combines Tesamorelin 5mg, Ipamorelin 5mg, and MOTS-C 10mg. Tesamorelin is a modified 44-amino-acid GHRH analog used to study receptor activation and downstream growth-hormone-axis signals. Ipamorelin is a modified five-residue peptide studied as a selective GHS-R1a, or ghrelin-receptor, agonist. MOTS-C is a 16-amino-acid mitochondrial-derived peptide examined in metabolic-stress, nutrient-sensing, and AMPK-related models.
Together, the set supports controlled work across GHRH-receptor and ghrelin-receptor signaling at 5mg vial strengths alongside mitochondrial and AMPK-related pathways. Each retail product stays in its own lyophilized vial, so the bundle does not create a new formulation or establish a proven combined effect.
How It Works
Tesamorelin models GHRH-receptor signaling: Receptor engagement supports controlled measurement of cAMP-linked pituitary and downstream pathway markers.
Ipamorelin engages GHS-R1a: This ghrelin-receptor route provides a defined growth-hormone-secretagogue signal in experimental models.
MOTS-C connects mitochondrial and metabolic-stress research: Preclinical work examines folate-cycle changes, AICAR signaling, and downstream AMPK activation.
One certificate per vial
Independent third-party HPLC assesses each compound against its ≥99% purity target, while mass spectrometry confirms identity. For each vial, the results are documented in one combined, batch-specific COA report.
- Lot
- MS431
- Reported
- 2026-06-01
- Identity (LC-MS)
- Confirmed
- Purity (HPLC-UV)
- 99.64%
- Net content
- 10.59 mg
- Appearance
- White lyophilized powder
Why Source from 321 Peptides?
Lot history 7 released lots
Every batch released under each vial in this bundle, with the figure reported for each. Vials are shipped from current stock.
| Compound | Lot | Reported | Purity | Net content | COA |
|---|---|---|---|---|---|
| Tesamorelin 5mg | TE-76080 | 2026-05-06 | 99.46% | 5.01 mg | Pending |
| TE-76657 | 2026-05-02 | 99.58% | 5.02 mg | Pending | |
| TE-75503 | 2026-04-08 | 99.49% | 5.01 mg | Pending | |
| MOTS-C 10mg | MS431 | 2026-06-01 | 99.64% | 10.59 mg | |
| MO-57344 | 2026-05-06 | 99.46% | 10.02 mg | Pending | |
| MO-57921 | 2026-05-02 | 99.58% | 10.03 mg | Pending | |
| MO-56767 | 2026-04-08 | 99.49% | 10.01 mg | Pending |